Indirect costs in chronic obstructive pulmonary disease: a review of the economic burden on employers and individuals in the United States
- PMID: 24672234
- PMCID: PMC3964024
- DOI: 10.2147/COPD.S57157
Indirect costs in chronic obstructive pulmonary disease: a review of the economic burden on employers and individuals in the United States
Abstract
Objective: To review and summarize existing literature on the indirect burden of chronic obstructive pulmonary disease (COPD) in the US.
Methods: Medline, Scopus, and OvidSP databases were searched using defined search terms to identify relevant studies. Eligible studies were published in English between January 2000 and April 2012 and calculated the indirect burden of COPD in a US population in terms of prevalence, incidence or costs of productivity loss, disability, morbidity, or mortality.
Results: Of 53 studies identified, eleven met eligibility criteria, with data years spanning 1987-2009. Estimates of workforce participation range from 56% to 69% among individuals with COPD and from 65% to 77% among individuals without COPD. Approximately 13%-18% of those with COPD are limited in the amount or type of work they can do and one-third or more experience general activity limitation. Estimates of restricted activity days range from 27-63 days per year. Estimates of mean annual sick leave and/or disability days among employed individuals with COPD range from 1.3-19.4 days. Estimates of bed confinement range from 13-32 days per year. Estimated mean annual indirect costs were $893-$2,234/person (US dollars) with COPD ($1,521-$3,348 in 2010 [US dollars]) and varied with the population studied, specific cost outcomes, and economic inputs. In studies that assessed total (direct and indirect) costs, indirect costs accounted for 27%-61% of total costs, depending on the population studied.
Conclusions: COPD is associated with substantial indirect costs. The disease places a burden on employers in terms of lost productivity and associated costs and on individuals in terms of lost income related to absenteeism, activity limitation, and disability. Consideration of indirect as well as direct costs is necessary to gain a more complete view of the societal burden of COPD.
Keywords: chronic obstructive pulmonary disease; disability; economics; indirect costs; productivity.
Figures
Similar articles
-
The direct and indirect costs of managing chronic obstructive pulmonary disease in Greece.Int J Chron Obstruct Pulmon Dis. 2017 May 10;12:1395-1400. doi: 10.2147/COPD.S132825. eCollection 2017. Int J Chron Obstruct Pulmon Dis. 2017. PMID: 28546747 Free PMC article.
-
Economic burden of COPD in a Swedish cohort: the ARCTIC study.Int J Chron Obstruct Pulmon Dis. 2018 Jan 11;13:275-285. doi: 10.2147/COPD.S149633. eCollection 2018. Int J Chron Obstruct Pulmon Dis. 2018. PMID: 29391785 Free PMC article.
-
The contribution of symptoms and comorbidities to the economic impact of COPD: an analysis of the German COSYCONET cohort.Int J Chron Obstruct Pulmon Dis. 2017 Dec 4;12:3437-3448. doi: 10.2147/COPD.S141852. eCollection 2017. Int J Chron Obstruct Pulmon Dis. 2017. PMID: 29270005 Free PMC article.
-
Assessment of the economic burden of COPD in the U.S.: a review and synthesis of the literature.COPD. 2006 Dec;3(4):211-8. doi: 10.1080/15412550601009396. COPD. 2006. PMID: 17361502 Review.
-
Economic Burden of Chronic Obstructive Pulmonary Disease (COPD): A Systematic Literature Review.Int J Chron Obstruct Pulmon Dis. 2020 Feb 26;15:439-460. doi: 10.2147/COPD.S234942. eCollection 2020. Int J Chron Obstruct Pulmon Dis. 2020. PMID: 32161455 Free PMC article.
Cited by
-
Relationship of airflow limitation severity with work productivity reduction and sick leave in a Japanese working population.Int J Chron Obstruct Pulmon Dis. 2016 Mar 16;11:567-75. doi: 10.2147/COPD.S99786. eCollection 2016. Int J Chron Obstruct Pulmon Dis. 2016. PMID: 27042045 Free PMC article.
-
Economic impact of chronic obstructive pulmonary disease: A cross-sectional study at teaching hospital in South India.J Family Med Prim Care. 2018 Sep-Oct;7(5):1002-1006. doi: 10.4103/jfmpc.jfmpc_75_16. J Family Med Prim Care. 2018. PMID: 30598947 Free PMC article.
-
Investigating pulmonary and systemic pharmacokinetics of inhaled olodaterol in healthy volunteers using a population pharmacokinetic approach.Br J Clin Pharmacol. 2016 Mar;81(3):538-52. doi: 10.1111/bcp.12780. Epub 2016 Feb 17. Br J Clin Pharmacol. 2016. PMID: 26348533 Free PMC article. Clinical Trial.
-
Does lung function predict the risk of disability pension? An 11-year register-based follow-up study.BMC Public Health. 2020 Feb 3;20(1):165. doi: 10.1186/s12889-020-8277-9. BMC Public Health. 2020. PMID: 32013933 Free PMC article.
-
Vaccine Effectiveness Against Influenza-Associated Lower Respiratory Tract Infections in Hospitalized Adults, Louisville, Kentucky, 2010-2013.Open Forum Infect Dis. 2020 Jun 30;7(7):ofaa262. doi: 10.1093/ofid/ofaa262. eCollection 2020 Jul. Open Forum Infect Dis. 2020. PMID: 32715020 Free PMC article.
References
-
- National Heart, Lung, and Blood Institute . Morbidity and Mortality: 2012 Chart Book on Cardiovascular, Lung and Blood Diseases. Bethesda: National Institutes of Health; 2012.
-
- Hoyert DL, Xu JQ. Deaths: preliminary data for 2011. Natl Vital Stat Rep. 2012;61(6):1–65. - PubMed
-
- Toy EL, Gallagher KF, Stanley EL, Swensen AR, Duh MS. The economic impact of exacerbations of chronic obstructive pulmonary disease and exacerbation definition: a review. COPD. 2010;7(3):214–228. - PubMed
-
- Dalal AA, Shah M, D’Souza AO, Rane P. Costs of COPD in the exacerbations in the emergency department and inpatient setting. Respir Med. 2011;105(3):454–460. - PubMed
-
- Wang PS, Beck A, Berglund P, et al. Chronic medical conditions and work performance in the health and work performance questionnaire calibration surveys. J Occup Environ Med. 2003;45(12):1303–1311. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
